Triple-G Agonist UBT251 Lowers HbA1c By Up To 2.16% In Chinese Phase 2 Diabetes Trial

Promising topline phase 2 results were reported for investigational diabetes drug UBT251 in Chinese patients by United Laboratories International Holdings (TUL) and Novo Nordisk (NVO). These early-stage positive readouts could support further development and create modest upside for the sponsors' equity on subsequent detailed data or advancement decisions.

Analysis

Promising topline phase 2 results were reported for investigational diabetes drug UBT251 in Chinese patients by United Laboratories International Holdings (TUL) and Novo Nordisk (NVO). These early-stage positive readouts could support further development and create modest upside for the sponsors' equity on subsequent detailed data or advancement decisions.